Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 158.23 Million SEK | 54.54% |
| 2022 | 102.38 Million SEK | 10.07% |
| 2021 | 93.01 Million SEK | 52.41% |
| 2020 | 61.02 Million SEK | 0.79% |
| 2019 | 60.54 Million SEK | 75.16% |
| 2018 | 34.56 Million SEK | 51.17% |
| 2017 | 22.86 Million SEK | 23.33% |
| 2016 | 18.54 Million SEK | 39.74% |
| 2015 | 13.26 Million SEK | 60.79% |
| 2014 | 8.25 Million SEK | -7.41% |
| 2013 | 8.91 Million SEK | 46.56% |
| 2012 | 6.08 Million SEK | 112.91% |
| 2011 | 2.85 Million SEK | 78.95% |
| 2010 | 1.59 Million SEK | 61.84% |
| 2009 | 986.17 Thousand SEK | 159.76% |
| 2008 | 379.65 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 29.47 Million SEK | -26.43% |
| 2024 Q1 | 40.05 Million SEK | 46.7% |
| 2023 Q1 | 72.34 Million SEK | 339.06% |
| 2023 Q2 | 31.47 Million SEK | -56.5% |
| 2023 Q3 | 30.18 Million SEK | -4.08% |
| 2023 FY | 158.23 Million SEK | 54.54% |
| 2023 Q4 | 27.3 Million SEK | -9.54% |
| 2022 Q2 | 24.98 Million SEK | -26.45% |
| 2022 FY | 102.38 Million SEK | 10.07% |
| 2022 Q3 | 26.96 Million SEK | 7.96% |
| 2022 Q4 | 16.47 Million SEK | -38.9% |
| 2022 Q1 | 33.96 Million SEK | -11.11% |
| 2021 Q3 | 17.64 Million SEK | -16.97% |
| 2021 Q4 | 38.2 Million SEK | 116.54% |
| 2021 FY | 93.01 Million SEK | 52.41% |
| 2021 Q1 | 15.91 Million SEK | -16.22% |
| 2021 Q2 | 21.24 Million SEK | 33.49% |
| 2020 Q3 | 14.48 Million SEK | -6.67% |
| 2020 Q4 | 18.99 Million SEK | 31.15% |
| 2020 Q1 | 11.47 Million SEK | -5.58% |
| 2020 FY | 61.02 Million SEK | 0.79% |
| 2020 Q2 | 15.52 Million SEK | 35.27% |
| 2019 FY | 60.54 Million SEK | 75.16% |
| 2019 Q4 | 12.15 Million SEK | -50.53% |
| 2019 Q1 | 12.22 Million SEK | 16.56% |
| 2019 Q2 | 11.6 Million SEK | -5.01% |
| 2019 Q3 | 24.56 Million SEK | 111.65% |
| 2018 Q2 | 8.73 Million SEK | 38.55% |
| 2018 FY | 34.56 Million SEK | 51.17% |
| 2018 Q4 | 10.48 Million SEK | 13.88% |
| 2018 Q3 | 9.2 Million SEK | 5.42% |
| 2018 Q1 | 6.3 Million SEK | -9.62% |
| 2017 FY | 22.86 Million SEK | 23.33% |
| 2017 Q4 | 6.97 Million SEK | 31.94% |
| 2017 Q2 | 5.81 Million SEK | 21.23% |
| 2017 Q1 | 4.79 Million SEK | 15911.49% |
| 2017 Q3 | 5.28 Million SEK | -9.05% |
| 2016 FY | 18.54 Million SEK | 39.74% |
| 2016 Q4 | 29.94 Thousand SEK | -99.38% |
| 2016 Q2 | 4.59 Million SEK | -49.53% |
| 2016 Q1 | 9.1 Million SEK | 627.62% |
| 2016 Q3 | 4.81 Million SEK | 4.74% |
| 2015 Q3 | 6.73 Million SEK | 30.85% |
| 2015 Q4 | -1.72 Million SEK | -125.63% |
| 2015 FY | 13.26 Million SEK | 60.79% |
| 2015 Q1 | 3.11 Million SEK | 358.34% |
| 2015 Q2 | 5.14 Million SEK | 65.06% |
| 2014 Q3 | 2.21 Million SEK | -25.7% |
| 2014 FY | 8.25 Million SEK | -7.41% |
| 2014 Q1 | 2.37 Million SEK | 130.97% |
| 2014 Q2 | 2.98 Million SEK | 25.95% |
| 2014 Q4 | 680.06 Thousand SEK | -69.34% |
| 2013 Q1 | 2.01 Million SEK | 39.05% |
| 2013 FY | 8.91 Million SEK | 46.56% |
| 2013 Q4 | 1.02 Million SEK | -66.92% |
| 2013 Q3 | 3.1 Million SEK | 12.11% |
| 2013 Q2 | 2.76 Million SEK | 37.25% |
| 2012 FY | 6.08 Million SEK | 112.91% |
| 2012 Q2 | 1.14 Million SEK | 21.61% |
| 2012 Q3 | 2.11 Million SEK | 84.06% |
| 2012 Q4 | 1.44 Million SEK | -31.38% |
| 2012 Q1 | 944 Thousand SEK | 2.16% |
| 2011 Q1 | 455 Thousand SEK | -27.89% |
| 2011 Q2 | 575 Thousand SEK | 26.37% |
| 2011 Q3 | 784 Thousand SEK | 36.35% |
| 2011 Q4 | 924.08 Thousand SEK | 17.87% |
| 2011 FY | 2.85 Million SEK | 78.95% |
| 2010 Q2 | 318 Thousand SEK | 32.5% |
| 2010 FY | 1.59 Million SEK | 61.84% |
| 2010 Q1 | 240 Thousand SEK | -49.81% |
| 2010 Q4 | 631.01 Thousand SEK | 55.04% |
| 2010 Q3 | 407 Thousand SEK | 27.99% |
| 2009 Q3 | 238 Thousand SEK | 65.28% |
| 2009 Q1 | 120 Thousand SEK | 0.0% |
| 2009 FY | 986.17 Thousand SEK | 159.76% |
| 2009 Q4 | 478.17 Thousand SEK | 100.92% |
| 2009 Q2 | 144 Thousand SEK | 20.0% |
| 2008 FY | 379.65 Thousand SEK | 0.0% |
| 2008 Q1 | 106 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -172.311% |
| Ziccum AB (publ) | 3.74 Million SEK | -4122.898% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 74.313% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -213.424% |
| Mendus AB (publ) | 28.48 Million SEK | -455.453% |
| Intervacc AB (publ) | 8.01 Million SEK | -1874.198% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -3517.558% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 7.163% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -260.47% |
| Aptahem AB (publ) | 2.63 Million SEK | -5914.944% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -15188.116% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -205396.104% |
| Fluicell AB (publ) | 3.33 Million SEK | -4640.324% |
| Saniona AB (publ) | 16.84 Million SEK | -839.62% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -864.418% |
| Biovica International AB (publ) | 7.29 Million SEK | -2070.535% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -13053.117% |
| AcouSort AB (publ) | 10.55 Million SEK | -1399.687% |
| Xintela AB (publ) | 78 Thousand SEK | -202761.538% |
| Abliva AB (publ) | 137 Thousand SEK | -115397.81% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -174.708% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -7756.604% |
| OncoZenge AB (publ) | 3000.00 SEK | -5274300.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -101985.161% |
| CombiGene AB (publ) | 5.54 Million SEK | -2754.052% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 86.889% |
| Camurus AB (publ) | 1.71 Billion SEK | 90.784% |
| Corline Biomedical AB | 25.03 Million SEK | -532.169% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -2686.756% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -21846.186% |
| I-Tech AB | 120.86 Million SEK | -30.921% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -18.001% |
| Cyxone AB (publ) | 5.14 Million SEK | -2973.66% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -2144.426% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -1383.698% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -1309.004% |
| Nanologica AB (publ) | 1.44 Million SEK | -10865.489% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -298450.943% |
| BioInvent International AB (publ) | 71.46 Million SEK | -121.424% |
| Alzinova AB (publ) | 270 Thousand SEK | -58504.444% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -349.267% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -10715.437% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -5507.087% |
| Simris Alg AB (publ) | 4.35 Million SEK | -3534.175% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -121616.923% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 33.719% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -687865.217% |